BRPI1008955A2 - Terapia de combinação com derivados de tiocolchicina. - Google Patents

Terapia de combinação com derivados de tiocolchicina.

Info

Publication number
BRPI1008955A2
BRPI1008955A2 BRPI1008955-1A BRPI1008955A BRPI1008955A2 BR PI1008955 A2 BRPI1008955 A2 BR PI1008955A2 BR PI1008955 A BRPI1008955 A BR PI1008955A BR PI1008955 A2 BRPI1008955 A2 BR PI1008955A2
Authority
BR
Brazil
Prior art keywords
combination therapy
thiocolchicine derivatives
thiocolchicine
derivatives
therapy
Prior art date
Application number
BRPI1008955-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Neil P Desai
Vuong Trieu
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Publication of BRPI1008955A2 publication Critical patent/BRPI1008955A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5169Proteins, e.g. albumin, gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI1008955-1A 2009-03-13 2010-03-12 Terapia de combinação com derivados de tiocolchicina. BRPI1008955A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21007409P 2009-03-13 2009-03-13
PCT/US2010/027159 WO2010105172A1 (en) 2009-03-13 2010-03-12 Combination therapy with thiocolchicine derivatives

Publications (1)

Publication Number Publication Date
BRPI1008955A2 true BRPI1008955A2 (pt) 2015-09-01

Family

ID=42728818

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1008955-1A BRPI1008955A2 (pt) 2009-03-13 2010-03-12 Terapia de combinação com derivados de tiocolchicina.

Country Status (12)

Country Link
US (2) US20120189701A1 (OSRAM)
EP (1) EP2405750B1 (OSRAM)
JP (1) JP5725563B2 (OSRAM)
KR (1) KR101739598B1 (OSRAM)
CN (1) CN102427728A (OSRAM)
AU (2) AU2010224012B2 (OSRAM)
BR (1) BRPI1008955A2 (OSRAM)
CA (1) CA2755121A1 (OSRAM)
IL (1) IL215079A (OSRAM)
MX (1) MX2011009452A (OSRAM)
NZ (1) NZ595189A (OSRAM)
WO (1) WO2010105172A1 (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
EP2359859A1 (en) 2002-12-09 2011-08-24 Abraxis BioScience, LLC Compositions comprising albumin nanoparticles and methods of delivery of pharmacological agents
US8735394B2 (en) * 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
CA2598239C (en) 2005-02-18 2019-10-29 Abraxis Bioscience, Inc. Nanoparticulate formulations of taxanes and carrier proteins for use in combination chemotherapy
US7771751B2 (en) 2005-08-31 2010-08-10 Abraxis Bioscience, Llc Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
DK2117520T3 (en) 2006-12-14 2019-01-07 Abraxis Bioscience Llc BREAST CANCER THERAPY BASED ON HORMON RECEPTOR STATUS WITH NANOPARTICLES INCLUDING TAXAN
LT2481409T (lt) * 2007-03-07 2018-10-25 Abraxis Bioscience, Llc Nanodalelės, apimančios rapamiciną ir albuminą, kaip priešvėžinį agentą
DK2155188T3 (da) * 2007-06-01 2013-11-04 Abraxis Bioscience Llc Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft
AU2010236382B2 (en) 2009-04-15 2016-01-14 Abraxis Bioscience, Llc Prion-free nanoparticle compositions and methods
NZ602382A (en) 2010-03-26 2014-11-28 Abraxis Bioscience Llc Methods of treatment of hepatocellular carcinoma
ES2600912T3 (es) 2010-03-29 2017-02-13 Abraxis Bioscience, Llc Métodos para tratar el cáncer
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
WO2011153010A1 (en) 2010-06-04 2011-12-08 Abraxis Biosciences, Llc Methods of treatment of pancreatic cancer
JP6038123B2 (ja) 2011-04-28 2016-12-07 アブラクシス バイオサイエンス, エルエルシー ナノ粒子組成物の脈管内送達およびそれらの使用
SI2790675T1 (sl) 2011-12-14 2019-11-29 Abraxis Bioscience Llc Uporaba polimernih pomožnih snovi za liofilizacijo ali zamrzovanje delcev
EP2903610B1 (en) 2012-10-01 2021-11-03 Mayo Foundation For Medical Education And Research Cancer treatments
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
EP3698784A1 (en) 2013-03-12 2020-08-26 Abraxis BioScience, LLC Methods of treating lung cancer
CN110934852A (zh) 2013-03-14 2020-03-31 阿布拉科斯生物科学有限公司 治疗膀胱癌的方法
EP2924022A1 (en) * 2014-03-27 2015-09-30 INDENA S.p.A. Amorphous form of a thiocolchicine derivative
US20160143866A1 (en) * 2014-11-21 2016-05-26 Eli D. Ehrenpreis Combination Therapy for Administration of Monoclonal Antibodies
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
CN116585310A (zh) 2015-06-29 2023-08-15 阿布拉科斯生物科学有限公司 治疗上皮样细胞肿瘤的方法
KR101748120B1 (ko) * 2015-07-13 2017-06-16 서울대학교산학협력단 나노입자-유리체 기반 단백질 복합체를 유효성분으로 포함하는 혈관신생억제용 조성물 및 이의 용도
AU2019239953B2 (en) 2018-03-20 2025-01-02 Abraxis Bioscience, Llc Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin
EP4051241A4 (en) 2019-10-28 2023-12-06 Abraxis BioScience, LLC PHARMACEUTICAL COMPOSITIONS OF ALBUMIN AND RAPAMYCIN

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
WO1998045331A2 (en) 1997-04-07 1998-10-15 Genentech, Inc. Anti-vegf antibodies
US6797691B1 (en) 1997-07-23 2004-09-28 Northwestern University Methods and compositions for inhibiting angiogenesis
KR20010085261A (ko) 1998-05-29 2001-09-07 빙검 더글라스 에이. 티로신 키나제 Src를 사용하는, 맥관형성의 조절에유용한 방법 및 조성물
EP1171117A4 (en) 1999-04-22 2002-08-07 American Bioscience Inc LONG-TERM ADMINISTRATION OF PHARMACOLOGICALLY ACTIVE AGENTS
IT1318401B1 (it) * 2000-03-17 2003-08-25 Indena Spa Derivati di n-desacetiltiocolchicina e composizioni farmaceutiche cheli contengono.
US20040143004A1 (en) 2002-02-26 2004-07-22 Joseph Fargnoli Metronomic dosing of taxanes
ES2428354T3 (es) 2002-09-18 2013-11-07 Trustees Of The University Of Pennsylvania Rapamicina para usar en la inhibición o prevención de la neovascularización coroidea
EP2359859A1 (en) 2002-12-09 2011-08-24 Abraxis BioScience, LLC Compositions comprising albumin nanoparticles and methods of delivery of pharmacological agents
WO2005117876A1 (en) 2004-06-01 2005-12-15 University Of Virginia Patent Foundation Dual small molecule inhibitors of cancer and angiogenesis
CA2598239C (en) * 2005-02-18 2019-10-29 Abraxis Bioscience, Inc. Nanoparticulate formulations of taxanes and carrier proteins for use in combination chemotherapy
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
AU2006284657B2 (en) 2005-08-31 2012-07-19 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
US20080280987A1 (en) 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
US20100166869A1 (en) 2007-05-03 2010-07-01 Desai Neil P Methods and compositions for treating pulmonary hypertension
CN101077335A (zh) * 2007-06-29 2007-11-28 济南康泉医药科技有限公司 一种含酪氨酸激酶抑制剂的抗癌组合物

Also Published As

Publication number Publication date
JP2012520323A (ja) 2012-09-06
IL215079A (en) 2016-11-30
KR101739598B1 (ko) 2017-06-08
JP5725563B2 (ja) 2015-05-27
US20120189701A1 (en) 2012-07-26
MX2011009452A (es) 2011-11-29
CN102427728A (zh) 2012-04-25
AU2016208343A1 (en) 2016-08-18
AU2010224012B2 (en) 2016-04-28
EP2405750A4 (en) 2014-01-15
EP2405750A1 (en) 2012-01-18
CA2755121A1 (en) 2010-09-16
US20170105951A1 (en) 2017-04-20
AU2010224012A1 (en) 2011-11-03
IL215079A0 (en) 2011-11-30
KR20110128339A (ko) 2011-11-29
NZ595189A (en) 2013-08-30
WO2010105172A1 (en) 2010-09-16
EP2405750B1 (en) 2018-05-09

Similar Documents

Publication Publication Date Title
BRPI1008955A2 (pt) Terapia de combinação com derivados de tiocolchicina.
HUS1700041I1 (hu) Kombinált afukozilált anti-CD20 antitest terápia bendamusztinnal
SI2324831T1 (sl) Terapija s pirfenidonom, izogibajoäśa se fluvoksaminu
BRPI1008949A2 (pt) Cetoenóis haloalquilmetilenóxi-fenil-substituídos.
BRPI1016117A8 (pt) derivados de isoxazol-isoxazol e isoxazol-isotiazol.
BRPI0917980A2 (pt) subcanalização com aumento de potência
BRPI1009415A2 (pt) escova de dentes.
BRPI1011527A2 (pt) derivados de triazina substituídos com ureidofenil e suas aplicações terapêuticas.
UY33125A (es) Diaza-espiro-[5,5]-undecanos
PT2484669E (pt) Derivados de fenol
BRPI0910534A2 (pt) terapia antiviral
BRPI0917446A2 (pt) derivados de acilaminobenzamida.
NO20091908A (no) Integraløfteren
DE112010001215A5 (de) Gurtaufrollersystem mit einsteuerglied
IT1396487B1 (it) Convogliatore.
BRPI0920743A2 (pt) ribonucleases terapeuticas
BRPI1015154A2 (pt) unidade de potência.
BRPI1016192A2 (pt) derivados de soxazol.
DK2442870T3 (da) Pyrazinooxazepin-derivater.
BRPI0906714A2 (pt) Derivados de oxazepinopirimidona heteroarilamida substituídos.
BR112012001062A2 (pt) laminados com microtextura.
EP2509287A4 (en) SLIDING AND TILTING MECHANISM
BRPI1013966A2 (pt) microensaio de esterilidade rápida.
BR112012014459A2 (pt) derivados de pirrolidina.
PL2090199T3 (pl) Tułów

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL